Eledon Pharmaceuticals to Participate in Two Upcoming Conferences
- A panel discussion with
Steven Perrin, Ph.D., President and Chief Scientific Officer, titled “ALS -- New Treatment Paradigm with More MoAs on the Way?” at the Cantor Neurology & Psychiatry Conferenceon Thursday, October 6, 2022at 1:20 p.m. ET; and
- An oral presentation by
Jeff Bornstein, M.D., Chief Medical Officer, titled "Tegoprubart (AT-1501) is safe and well tolerated and reduces inflammation in patients with ALS” at the ALS One 5th Annual ALS Research Symposium on Friday, October 7, 2022at 11:40 a.m. ET.
Both presentations will be available to registered conference attendees only. For additional information or to request a meeting with management, please contact conference representatives.
Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.
Source: Eledon Pharmaceuticals, Inc.